Home / Business and Economy / Pharma Veteran Joins Lipocine Board
Pharma Veteran Joins Lipocine Board
3 Aug
Summary
- Michael J. Grissinger appointed to Lipocine's Board of Directors.
- Grissinger brings decades of experience in pharma licensing and M&A.
- His expertise aims to advance Lipocine's pipeline and partnerships.
Lipocine Inc. has welcomed Michael J. Grissinger to its Board of Directors, a move effective August 3, 2026. Grissinger's appointment is expected to significantly bolster the biopharmaceutical company's strategic initiatives.
With over two decades at Johnson & Johnson, Grissinger held key positions including Vice President and Head of Worldwide Pharmaceutical Licensing and Corporate Development. His tenure also involved leading the Business Development and Licensing Group for Johnson & Johnson's Immunology Therapeutic Area.
Grissinger's extensive dealmaking experience, gained from both Johnson & Johnson and previous roles at Ciba-Geigy, will be crucial. Lipocine aims to leverage his expertise to advance its pipeline and explore potential partnerships for its therapeutic assets.
He currently serves on the boards of Aprea Therapeutics and Adicet Bio, alongside advising several private biotech firms. Grissinger's background in finance, marketing, and business development, coupled with his academic achievements from Juniata College and Temple University, positions him to contribute valuable judgment to Lipocine.
